Arcus Biosciences (RCUS) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.09), $0.06 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.99 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- CompX International (CIX) Reports Q3 EPS of $0.44
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
